3,5-dimethoxycinnamamide | 124805-94-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 3,5-dimethoxycinnamamide
• 英文别名: 3-(3,5-Dimethoxyphenyl)prop-2-enamide；(E)-3-(3,5-dimethoxyphenyl)prop-2-enamide
• CAS: 124805-94-3
• 化学式: C₁₁H₁₃NO₃
• 分子量: 207.229
• InChiKey: FBRYJRYXVCLPAD-ONEGZZNKSA-N

物化性质

• 沸点：
  434.9±45.0 °C(Predicted)
• 密度：
  1.156±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  61.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO<br/>[FR] ANTAGONISTES DU RÉCEPTEUR EP2 DES PROSTAGLANDINES, DÉRIVÉS, COMPOSITIONS ET UTILISATIONS ASSOCIÉS
  申请人：UNIV EMORY

  公开号：WO2015167825A1

  公开（公告）日：2015-11-05

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  该披露涉及前列腺素受体EP2拮抗剂，衍生物，组合物以及相关方法。在某些实施例中，该披露涉及治疗或预防EP2受体激活在生理作用中起作用的疾病和疾病的方法，例如但不限于脑损伤，炎症性疾病，癫痫后的神经炎症，疼痛，子宫内膜异位症，癌症，类风湿性关节炎，皮肤炎症，血管炎症，结肠炎和神经系统疾病，通过向需要的受试者给予包含本文所披露的化合物的药物组合物进行治疗。
• Improvements in or relating to rodent control
  申请人：BRITISH TECHNOLOGY GROUP LIMITED

  公开号：EP0373909A2

  公开（公告）日：1990-06-20

  Compounds of formula (I) wherein X¹ and X⁵ are each separately selected from hydrogen and C₁₋₄alkyl, halogeno and halogeno-substituted C₁₋₄ alkyl groups; X², X³ and X⁴ are each separately selected from hydrogen and C₁₋₄ alkyl, hydroxy, C₁₋₄ alkoxy and phenoxy groups; R¹ and R² are each separately selected from hydrogen and C₁₋₄ alkyl groups; R³ and R⁴ are each hydrogen or together constitute the second bond of a carbon-carbon double bond joining -CR¹R³- and -CR²R⁴-; and Y is carbamoyl or carbamoyl N-substituted by one or two of the same or different C₁₋₄ alkyl groups are of value as rodent repellents.

  式(I)化合物 其中 X¹ 和 X⁵ 各自分别选自氢和 C₁₋₄ 烷基、卤代和卤代取代的 C₁₋₄ 烷基；X²、X³ 和 X⁴ 分别选自氢和 C₁₋₄ 烷基、羟基、C₁₋₄ 烷氧基和苯氧基；R¹ 和 R² 分别选自氢和 C₁₋₄ 烷基；R³和R⁴各自为氢或共同构成连接-CR¹R³-和-CR²R⁴-的碳-碳双键的第二个键；以及 Y 为氨基甲酰基或由一个或两个相同或不同的 C₁₋₄烷基取代的氨基甲酰基，具有驱鼠剂的价值。
• Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
  申请人：Emory University

  公开号：US10052332B2

  公开（公告）日：2018-08-21

  The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.

  本公开涉及前列腺素受体EP2拮抗剂、衍生物、组合物及其相关方法。在某些实施方案中，本公开涉及通过向有需要的受试者施用包含本文公开的化合物的药物组合物来治疗或预防 EP2 受体激活具有生理作用的病症和疾病的方法，这些病症和疾病包括但不限于脑损伤、炎症性疾病、癫痫发作后的神经损伤、疼痛、子宫内膜异位症、癌症、类风湿性关节炎、皮肤炎症、血管炎症、结肠炎和神经系统疾病。
• Improvements in or relating to avian control
  申请人：NATIONAL RESEARCH DEVELOPMENT CORPORATION

  公开号：EP0321208B1

  公开（公告）日：1991-07-03
• PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO
  申请人：Emory University

  公开号：EP3137074B1

  公开（公告）日：2020-08-05